 |
|
Ovarian Cancer Trial Results
1. Early Chemotherapy to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
(Posted: 06/19/2009) - Women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose, according to findings presented at the 2009 ASCO meeting in Orlando.
2. Removal of Ovaries and Fallopian Tubes Cuts Cancer Risk for BRCA1/2 Carriers
(Posted: 02/24/2009) - Surgery that removes the ovaries and fallopian tubes is one of the most effective ways to decrease a woman's risk of breast and gynecologic cancer if she carries a BRCA1 or BRCA2 gene mutation, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
3. Ultrasound Expertise Important in the Diagnosis of Ovarian Cancer
(Posted: 02/25/2008) - Improving the quality of diagnostic ultrasound scans could significantly reduce unnecessary surgeries in women with suspected ovarian cancer who, in fact, have benign disease, according to the February 2008 issue of the Lancet Oncology.
4. Impact of Intraperitoneal Chemotherapy on Quality of Life During Ovarian Cancer Treatment
(Posted: 02/14/2007) - Women with ovarian cancer treated with intraperitoneal (IP)chemotherapy reported more side effects and a lower quality of life during their treatment compared to women receiving intravenous chemotherapy. However, at the end of one year, only neurological symptoms remained worse for the IP group, according to the Feb. 1, 2007, Journal of Clinical Oncology.
5. Review Confirms Effectiveness of Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
(Posted: 12/18/2006) - Combined data from 60 randomized clinical trials of advanced ovarian cancer showed that multidrug chemotherapy using a platinum-based drug and a taxane-based drug delivered directly into the abdomen (intraperitoneal chemotherapy) can help women survive a median of 5.5 years, according to the Nov. 15, 2006, Journal of the National Cancer Institute.
1 2 3 Next >
|
|
|
